CARBOPLATIN INJECTION BP 10 MG
CARBOPLATIN : 10 MG · DIN 02126680 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is CARBOPLATIN INJECTION BP?
CARBOPLATIN INJECTION BP 10 MG contains CARBOPLATIN : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02126680, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 11-Nov-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CARBOPLATIN INJECTION BP used for?
Treatment of ovarian cancer of epithelial origin in first line therapy, and in second line therapy after other treatments have failed.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is CARBOPLATIN INJECTION BP called?
The same molecule, CARBOPLATIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Carboplatin Accord | Latin | Australia |
| Paraplatin rtu | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02126680 |
|---|---|
| Brand name | CARBOPLATIN INJECTION BP |
| Generic / active ingredient | CARBOPLATIN : 10 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01XA02 CARBOPLATIN |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Nov-2017 |
| Original market date | 1997-07-30 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02126680 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2126680 |
| Brand name | CARBOPLATIN INJECTION BP |
| Active ingredient / INN | CARBOPLATIN : 10 MG |
| ATC code | L01XA02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01 |
| AHFS class | 10:00.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PFIZER CANADA ULC |
How is it administered?
Recommended dose for untreated adults: 400 mg/m2 as a single IV infusion over 15-60 minutes. Repeat every 4 weeks. Adjust dose for renal impairment or prior myelosuppressive therapy.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Diluted solutions stable for 24h at room temp or 48h under refrigeration. (Note: specific unopened storage temp not in provided text, but stability for dilutions is specified).
How is it supplied?
Clear glass vials of 5 mL, 15 mL, 45 mL and 60 mL, each wrapped in a clear plastic ONCO-TAIN sleeve. Preservative-free and latex-free.
Which pack is which?
| Strength on the label | 10 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Packaging as described in the monograph | Clear glass vials of 5 mL, 15 mL, 45 mL and 60 mL, each wrapped in a clear plastic ONCO-TAIN sleeve. Preservative-free and latex-free. |
| Storage | Diluted solutions stable for 24h at room temp or 48h under refrigeration. (Note: specific unopened storage temp not in provided text, but stability for dilutions is specified). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Contraindications
Severe myelosuppression; pre-existing severe renal impairment; history of severe allergic reactions to carboplatin or other platinum-containing compounds.
Warnings and precautions
Serious Warnings: Highly toxic, narrow therapeutic index, bone marrow suppression, fatal infections with live vaccines, hypersensitivity, and veno-occlusive disease.
Is CARBOPLATIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01XA02 CARBOPLATIN. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CARBOPLATIN INJECTION | 10 MG | LIQUID | TEVA CANADA LIMITED | MARKETED | DIN 02125439 |
| CARBOPLATIN INJECTION BP | 10 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02320371 |
| CARBOPLATIN INJECTION | 10 MG | SOLUTION | EUGIA PHARMA INC. | APPROVED | DIN 02535289 |
| CARBOPLATIN INJECTION | 10 MG | SOLUTION | OMEGA LABORATORIES LIMITED | DORMANT | DIN 02366053 |
| CARBOPLATIN INJECTION | 10 MG | SOLUTION | AURO PHARMA INC | APPROVED | DIN 02528916 |
| CARBOPLATIN INJECTION LIQ 10MG/ML | 10 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | DIN 01990438 |
| CARBOPLATIN INJECTION, BP | 10 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | DIN 02420228 |
| PARAPLATIN INJ 150MG/VIAL | 150 MG | POWDER FOR SOLUTION | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | CANCELLED POST MARKET | DIN 00680060 |
| PARAPLATIN-AQ INJ 10MG/ML | 10 MG | LIQUID | BRISTOL-MYERS SQUIBB CANADA | CANCELLED POST MARKET | DIN 00788759 |
Who else supplies CARBOPLATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CARBOPLATIN appears in 38 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CARBOPLATIN cost around the world?
CARBOPLATIN is listed on 7 national price registers Nexara tracks, across 43 pack listings published on 6 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Saudi Arabia | public | 6 | 12 | 01 Sep 2026 |
| South Africa | single exit price | 9 | 11 | 01 Sep 2026 |
| Romania | max producer price | 3 | 9 | 03 Sep 2026 |
| United Kingdom | hospital | 4 | 4 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| Australia | ex-manufacturer | 1 | 2 | 08 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.